Ongoing Clinical Research

OIC is at the forefront of clinical trials and cutting edge technology. Here, you can research study opportunities for HIV vaccines, HIV medications, and Hepatitis C medications.

If you are eligible, you will receive study drugs, labs, and medical treatments related to the study at no cost.

HIV STUDIES

  • GSK200911 (CURRENTLY ENROLLING)
    • A phase 2a, Multicenter, randomized, adaptive, open-label, dose ranging study to evaluate the antiviral effect, safety, tolerability and pharmacokinetics of Cobicstat-boosted GSK2838232 monotherapy over 10 days in HIV-1 infected treatment-Naïve adults.
  • MK1439A-024 (CURRENTLY ENROLLING)
    • The study will evaluate the safety and efficacy of a switch to MK-1439A (MK-1439 [doravirine] plus lamivudine and tenofovir disoproxil fumarate) in HIV-1-infected participants virologically suppressed on a regimen of a ritonavir-boosted protease inhibitor and two nucleoside reverse transcriptase inhibitors. The primary hypothesis is that a switch to MK-1439A will be non-inferior to continuation of a ritonavir-boosted protease inhibitor-based regimen for 24 weeks, as assessed by the proportion of participants maintaining HIV-1 ribonucleic acid (RNA)
  • REPRIEVE (CURRENTLY ENROLLING)
    • People infected with HIV are at risk for cardiovascular disease.  This study will evaluate the use of pitavastatin to reduce the risk of CVD in adults infected with HIV who are on antiretroviral therapy.
  • PRO140_CD03 (CURRENTLY ENROLLING)
    • A phase 2b/3 multicenter study to assess the treatment strategy of using PRO140 SC as long acting single agent maintenance therapy for 48 weeks in virologically suppressed subjects with CCR5 topic HIV-1 Infection.
  • GS-US-382-3961 (CURRENTLY ENROLLING)
    • A Phase 1b, Randomized, Double-Blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of GS-9620 in Antiretroviral Treated HIV-1 Infected Controllers
  • AI438-047 (CURRENTLY ENROLLING)
    • The purpose of this study is to determine whether the BMS Attachment Inhibitor (BMS-663068) is effective in the treatment of heavily treatment experienced HIV-1 patients with multi-drug resistance.
  • PRO140-CD02 (CURRENTLY ENROLLING)
    • A multicenter, randomized, double-blind, placebo controlled trial, followed by a single-arm treatment of PRO140 in combination with optimized background therapy in treatment-experienced HIV-1 subjects.

HCV STUDIES

  • GS-US-366-1992 (CURRENTLY ENROLLING)
    • This study will evaluate efficacy of Ledipasvir/Sofosbuvir (LDV/SOF) as measured by the proportion of participants achieving hepatitis C virus (HCV) RNA below the lower limit of quantification (LLOQ) 12 weeks after the last dose of LDV/SOF (sustained virologic response (SVR) 12).This study will consist of 2 parts. In Part 1, the participants will be randomized to switch from stable antiretroviral (ARV) therapy to either E/C/F/TAF or F/R/TAF. The participants maintaining HIV-1 RNA < 50 copies/mL and tolerating E/C/F/TAF or F/R/TAF through Part 1 will continue to Part 2 where they will receive the LDV/SOF treatment
  • 3152-301-002 (CURRENTLY ENROLLING)
    •  A phase 3, multicenter, randomized, double blind, placebo controlled study to evaluate the efficacy and safety of Cenicriviroc for the treatment of Liver Fibrosis in adult subjects with Nonalcoholic Steatohepatitis.
  • GS-US- 367-2036 (PENDING)
    • A phase 3, open label study to investigate the efficacy and safety of
      Sofosbuvir/Velpatasvir/Voxilaprevir fixed dose combination for 12 weeks with chronic Hepatitis C virus and HIV coinfection who have been previously treated with direct-acting antiviral HCV therapy.
  • 3152-301-002 (CURRENTLY ENROLLING)
    • A phase 3, multicenter, randomized, double blind, placebo controlled study to evaluate the efficacy and safety of Cenicriviroc for the treatment of Liver Fibrosis in adult subjects with Nonalcoholic Steatohepatitis.

HIV PREVENTION (PrEP) STUDY 

  • GS-US-412-2055 (CURRENTLY ENROLLING)
    • Safety and efficacy of Emtricitabine and Tenofovir Alfenamide F-TAF fixed – dose combination once daily for pre-exposire in men and transgender women who have sex with men and are at risk of HIV-1 infection

OTHER STUDIES

  • REPRIEVE (CURRENTLY ENROLLING)
    • People infected with HIV are at risk for cardiovascular disease.  This study will evaluate the use of pitavastatin to reduce the risk of CVD in adults infected with HIV who are on antiretroviral therapy.

 

Source: ClinicalTrials.gov

Clinical Trial Inquiry

To schedule an appointment with one of our board certified specialists call
(407) 647-3960 or click here to request an appointment.